for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS

Latest Trade

87.83USD

Change

-0.55(-0.62%)

Volume

2,324,399

Today's Range

87.66

 - 

88.09

52 Week Range

77.04

 - 

98.52

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
88.38
Open
87.78
Volume
2,324,399
3M AVG Volume
41.41
Today's High
88.09
Today's Low
87.66
52 Week High
98.52
52 Week Low
77.04
Shares Out (MIL)
2,256.82
Market Cap (MIL)
216,248.90
Forward P/E
13.88
Dividend (Yield %)
3.63

Next Event

Q1 2021 Novartis AG Earnings Release

Latest Developments

More

FDA Approves Xolair Prefilled Syringe For Self-Injection Across All Indications

Novartis Pharmaceuticals Canada Inc Says Health Canada Approves Kesimpta For Relapsing Remitting Multiple Sclerosis

Novartis Appoints Karen Hale As Chief Legal Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG (ADR)

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Lead Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Steven Baert

Chief People & Organization Officer, Member of the Executive Committee

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

51.9K

2019

47.4K

2020

48.7K

2021(E)

52.2K
EPS (USD)

2018

5.150

2019

5.400

2020

5.780

2021(E)

6.343
Price To Earnings (TTM)
25.03
Price To Sales (TTM)
4.33
Price To Book (MRQ)
3.51
Price To Cash Flow (TTM)
14.88
Total Debt To Equity (MRQ)
67.23
LT Debt To Equity (MRQ)
49.43
Return on Investment (TTM)
8.54
Return on Equity (TTM)
6.45

Latest News

Latest News

Novartis agrees to make ingredients Roche's Actemra for COVID-19 patients

Swiss drugmaker Novartis has signed a deal to make ingredients for Roche's Actemra treatment that is being repurposed for people with COVID-19, the company said on Thursday.

Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

RPT-UPDATE 1-Roche, Novartis approvals in Europe signal more head-to-head competition

Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients.

Novartis says Kesimpta gets EU approval in multiple sclerosis

Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

Novartis closes U.S. gene therapy site as Zolgensma sales fell from Q3 to Q4

Novartis is laying off 400 people and closing a U.S. gene therapy location that it bought only two years ago to make its $2.1 million per patient treatment Zolgensma as sales momentum for the most expensive one-time treatment stalled last year.

In-house counsel on the move: Fox and Novartis add lawyers

Companies in sectors from television to healthcare expanded their in-house legal teams this week, including media giant Fox Corp and Novartis, a key player in the race to manufacture a COVID-19 vaccine.

BioNTech to be given EU approval for Marburg COVID-19 vaccine plant - source

The European Union's drugs regulator is set to grant German biotech firm BioNTech approval for the use of COVID-19 vaccines produced at its new site in the German city of Marburg, a person familiar with the matter told Reuters on Friday.

Novartis corrects chairman's comments about kickbacks case

Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last year risked violating the agreement.

Novartis says radioligand therapy improves prostate cancer survival

Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday.

Novartis radioligand therapy improves prostate cancer survival

Novartis' Lu-PSMA-617 radioligand therapy helped improve survival for patients with advanced castration-resistant prostate cancer in a phase III study, the Swiss drugmaker said on Tuesday.

Novartis, a key player in COVID-19 vaccine push, taps new chief legal officer

Novartis, a Swiss drugmaker that is helping Pfizer and BioNtech manufacture their COVID-19 vaccine, named Karen Hale its chief legal officer on Monday, after losing its top lawyer to rival Moderna earlier this month.

Novartis' canakinumab failed to improve survival in Phase III trial

Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.

Novartis joins CureVac's vaccine contractor line-up

German biotech firm CureVac has enlisted Swiss pharmaceutical giant Novartis to help produce its experimental COVID-19 vaccine, boosting a network of contract manufacturers ahead of results from a pivotal trial.

Novartis and Bill & Melinda Gates Foundation collaborate on therapy for sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation to fund the development of accessible single use gene therapies to cure sickle cell disease (SCD), the pharmaceuticals company said on Wednesday.

U.S. FDA approves expanded use of Novartis heart drug

The U.S. Food and Drug Administration has approved the expanded use of Novartis' heart failure medicine Entresto, the Swiss drugmaker said on Tuesday, boosting the drug's prospects to around $5 billion sales annually.

UPDATE 1-Novartis buys antibiotics business from GSK in generics push

Swiss drugmaker Novartis' generics division is buying a GlaxoSmithKline antibiotics business that includes the brands Zinnat, Zinacef and Fortum for up to $500 million, the drugmakers said on Thursday.

Swiss drugmaker Novartis to help make Pfizer-Biontech COVID-19 vaccine

Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Novartis to help Pfizer-Biontech produce COVID-19 vaccine

Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Novartis in talks on helping make COVID-19 vaccines, tests

Novartis is talking to other companies about helping to make vaccines and tests for COVID-19, the Swiss drugmaker said on Thursday without providing more details.

Novartis CEO renews commitment to Sandoz generics unit

Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up